2-(Ethylamino)ethyl 2-cyclohexyl-2-hydroxy-2-phenylacetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(Ethylamino)ethyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
• 化学式: C₁₈H₂₇NO₃
• 分子量: 305.4
• InChiKey: OAJAVRLBGOSCNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Muscarinic receptor antagonists
  申请人：Aggen James

  公开号：US20090306134A1

  公开（公告）日：2009-12-10

  Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

  本发明涉及一种多结合化合物，其为肌动蛋白受体拮抗剂。该发明的多结合化合物包含2至10个配体共价连接到一个或多个连接体上。每个配体是独立的，可以是肌动蛋白受体拮抗剂或变构调节剂，但至少其中一个配体是肌动蛋白受体拮抗剂。本发明的多结合化合物在治疗和预防慢性阻塞性肺疾病、慢性支气管炎、肠易激综合征、尿失禁等疾病方面具有用途。
• Pharmaceutical compositions for the treatment of gastro-intestinal diseases
  申请人：SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu

  公开号：EP0268868A2

  公开（公告）日：1988-06-01

  The invention relates to pharmaceutical compositions for the treatment of gastro-intestinal diseases, especially gastric and duodenal ulcers, which com­prise as a physiologically active ingredient the spirocyclic dipeptide cyclo(L-alanyl-1-amino-1-cyclo­pentanecarbonyl), preferably together with a physio­logically inert carrier substrate, and optionally an adjuvant, physiologically active component. The subject composition is designated for oral or par­enteral administration; it has a very low toxicity, is well tolerated and acts beneficially even at low dosage levels.

  本发明涉及用于治疗胃肠道疾病，特别是胃溃疡和十二指肠溃疡的药物组合物，其生理活性成分包括环(L-丙氨酰-1-氨基-1-环戊基羰基)螺环二肽，优选与生理惰性载体基质和可选的辅助生理活性成分一起使用。 该主题组合物指定用于口服或肠道外给药；其毒性极低，耐受性良好，即使在低剂量水平下也能发挥有益作用。
• PHARMACEUTICAL COMBINATIONS
  申请人：Caltabiano Stephen

  公开号：US20120035118A1

  公开（公告）日：2012-02-09

  Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
• US5182285A
  申请人：——

  公开号：US5182285A

  公开（公告）日：1993-01-26
• US7456203B2
  申请人：——

  公开号：US7456203B2

  公开（公告）日：2008-11-25